InjectionAnti Cancer

Bortezomib Injection

Bortezomib · Proteasome inhibitor (antineoplastic)

InjectionAnti Cancer

Bortezomib InjectionProspero Healthcare

Bortezomib is classed as a proteasome inhibitor (antineoplastic) and is supplied as an injection. Its standard indications include multiple myeloma and Mantle cell lymphoma, and it is offered for pharmaceutical supply and export.

Uses

Multiple myeloma
Mantle cell lymphoma

Enquire about this product

Specifications are indicative; availability, composition, pack sizes and registration requirements may vary by destination market.

01Specification

Product details

Composition: Bortezomib
Available strengthsIndicative: 1 mg · 2 mg · 3.5 mg
Dosage form: Injection
Therapeutic category: Anti Cancer Critical Care Injection Infusion
Therapeutic class: Proteasome inhibitor (antineoplastic)
Packing: Vial or ampoule, single unit or tray pack
Storage: Store below 25 °C, protected from light. Do not freeze.

02Related

From the same category

View the category